Scribe Therapeutics priced an upsized IPO at the top of its range, raising about $129 million gross as it begins trading on Nasdaq under ticker SCTX. The company sold 8.6 million shares at $15 apiece, after setting out a $13–$15 price band, signaling strong market reception for its in vivo CRISPR platform. Scribe’s pipeline targets lipid-associated genes in cardiovascular and metabolic diseases, with STX-1150 in a phase 1 study enrolling in Australia. The proceeds are also earmarked for additional preclinical-to-clinic work including APOC3-targeting STX-1400 and LPA-targeting STX-1200. The IPO adds another data point to the sector’s willingness to fund gene-editing beyond rare diseases, with investors explicitly underwriting first-in-human execution risk in cardiometabolic indications.